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1. Introduction 
There are several synonyms for Amyotrophic Lateral Sclerosis (ALS) which include Motor 
Neuron Disease (MND), Charcot's disease, and Lou Gehrig's disease. The latter is named after 
the American baseball professional Lou Gehrig, who died of ALS in the 1940s (Miller, 2011).  
The symptoms of motor neuron disease (MND) have first been described by several 
neurologists by the mid-19th century. The French neurologist Charcot defined the nosological 
entity “amyotrophic lateral sclerosis” (ALS) some years later (historic aspects of ALS are 
reviewed in (Eisen, 2007; Mitsumoto et al., 2006; Oliveira & Pereira, 2009; Rowland, 2001; 
Wijesekera & Leigh, 2009)).  
In the present understanding, MND comprehends a spectrum of different 
neurodegenerative syndromes which show a common neuropathology, i. e. the progressive 
degeneration of motor neurons.  
These syndromes include the “classical” ALS, progressive bulbar palsy (PBP), progressive 
muscular atrophy (PMA), primary lateral sclerosis (PLS), flail arm syndrome (Vulpian-
Bernhardt syndrome), flail leg syndrome, and ALS with multi-system involvement (e.g., Fronto-
Temporal Dementia, FTD) (Fig. 1) (reviewed in Lillo & Hodges, 2009; Silani et al., 2011).  
2. Diagnostic criteria 
2.1 Clinical features 
The diagnosis of ALS is based on a catalogue of criteria specified by the World Federation of 
Neurology (www.wfneurology.org). These criteria are known as the “El Escorial” criteria, 
named after the Spanish historic site El Escorial. The original criteria of 1994 (Brooks, 1994; 
Mitsumoto, 1997) have been revised in 1998 (Brooks et al., 2000; Ross et al., 1998), which are 
known as the “Airlie House” criteria, named after the conference site at Warrenton, VA, 
U.S.A. In 2006, a consensus conference at Awaji-shima defined criteria of electromyographic 
and nerve conduction measurements for the diagnosis of ALS (de Carvalho et al., 2008). 
The clinical features comprehend the presence of (i) lower motorneuron (LMN) signs such 
as the loss of muscle strength, muscular atrophy, fasciculations, hyporeflexia, hypotonicity 
or flaccidity, or muscle cramps, in at least two limbs; (ii) upper motorneuron (UMN) signs 
such as extensor plantar responses, spasticity, or pathologic hyperreflexia, in at least one 
region (bulbar, cervical, or lumbosacral), and (iii) the progression of the disease defined as 
increasing symptomatic impairment by history in the same region or new regions (Ferguson 
& Elman, 2007).  
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Fig. 1. Spectrum of motor neuron disease (MND). Currently, the understanding of MND 
comprehends a variety of neurodegenerative syndromes with progressive degeneration of 
motor neurons.  
Neuropathological findings defining the MND spectrum are, on the cellular level, the 
progressive degeneration of upper and/or lower motor neurons, respectively, and on the 
molecular level, the presence of intraneuronal inclusion bodies which are immunopositive 
for ubiquitin-(Ub) and the 43 kB TAR DNA-binding protein (TDP-43) (reviewed in 
Colombrita et al., 2011; Geser et al., 2010), named Bunina, or Hirano, inclusion bodies 
(Rowland, 2009). 
Moreover, sensory signs (except those attributable to aging), neurogenic sphincter 
abnormalities, other progredient diseases of the central nervous system (CNS) or peripheral 
nervous system (PNS) must be absent. Additionally, ALS-like syndromes must be ruled out. 
These include myelopathy, structural lesions of the spinal cord, multifocal motor 
neuropathy, hyperthyroidism, hyperparathyroidism, hematologic malignancy associated 
with monoclonal gammopathy, lead poisoning, a history of radiation to the CNS, and 
hexosaminidase A deficiency in patients younger than 30 years of age.  
The revised criteria defined a certain probability level for the diagnostic criteria (Brooks et 
al., 2000), which have been questioned by the later electrophysiological consensus (de 
Carvalho et al., 2008; Sathasivam, 2010). 
At present, a consensus conference has defined morphological markers by MRI, which may 
lead to a biomarker for ALS diagnosis (Kiernan et al., 2011; Turner et al.).  
2.2 Neuropsychiatry of ALS 
Only in recent years, psychiatric and behavioural symptoms of ALS patients came into the 
focus of interest. It has become clear that psychiatric symptoms are not only secondary 
phenomena of a disabilitating disease, but are also inherent and specific in ALS. On the 
other hand, the etiopathological connections remain unknown.  
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With regard to the diagnoses and prevalence of these in ALS patients, there are only few 
data available, which are summarized in Table 1. 
 
Psychiatric Diagnosis 
Prevalence (percentages, rounded) and 
reference 
Depression 
30(Atassi et al., 2011; Lillo et al., 2011); 15 
(Ferentinos et al., 2011); 10 (Kurt et al., 
2007) 
Dementia 10 (Lillo et al., 2011) 
Stereotypical behavior 20 (Lillo et al., 2011) 
Reduction in motivation 80 (Lillo et al., 2011) 
Apathy 40 (Lillo et al., 2011) 
Cognitive impairment 50 (Woolley & Jonathan, 2008) 
Sleep disturbances Unknown (Hetta & Jansson, 1997) 
Fatigue Unknown 
Psychosis Unknown 
Table 1. Common psychiatric symptoms and diagnoses reported in ALS patients.  
In the following paragraphs, I will shortly describe the major psychiatric abnormalities in 
ALS patients and current findings. 
2.2.1 Dementia 
In the concept of a “continuum” of TDP-43 proteinopathies (Geser et al., 2009), ALS is 
classified together with fronto-temporal dementia (Giordana et al., 2011; Lillo & Hodges, 
2009; Nakano, 2000; Woolley & Jonathan, 2008; Yoshida, 2004; Zago et al., 2011). This has 
also been shown on the morphological level (Tsujimoto et al., 2011).  
Another pathophysiological pathway discussed in the pathogenesis of FTD is the 
progranulin pathway (Sleegers et al., 2010).  
Cognitive impairment and frontal lobe dysfunction is seen in about 40-60% of ALS patients 
(Abrahams et al., 1996; Evdokimidis et al., 2002; Witgert et al., 2009). 
2.2.2 Sleep 
In the current understanding, it is difficult to distinguish whether psychiatric abnormalities 
in ALS patients are integral part of the CNS disease, or if they are a secondary phenomenon. 
For example, sleep disturbances are a common problem in ALS patients, but besides 
anxiety, they may also result from reduced mobility, muscle cramps, or swallowing 
problems (Hetta & Jansson, 1997).  
2.2.3 Fatigue 
Fatigue is also a common problem in ALS patients, which does not describe physical 
exhaustion, but a pathological state of mind (Jackson & Bryan, 1998; Lou, 2008). 
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2.2.4 Depression and anxiety 
The patients know about the devastating nature of ALS with only a short survival time 
remaining at the point of time at diagnosis, with a deteriorating quality of life, and without a 
pharmacological treatment option towards “healing”. Therefore, a high prevalence of 
depression and anxiety in ALS patients would be expected. On the other hand, prevalence 
rates for depression in ALS patients range from 0-44% in the literature, whereas structured 
interviewing according to DSM-IV criteria reveals rates of 9-11% (Averill et al., 2007; 
Ferentinos et al., 2011; Kurt et al., 2007). Prevalence rates for anxiety in ALS have been 
reported with 0-30% (Kurt et al., 2007). Interestingly, the rate of depression and anxiety is 
not as high as expected (Huey et al., 2010; McLeod & Clarke, 2007; Norris et al., 2010), which 
means that the quality of life addressed by an individual is not dependent on the remaining 
lifetime. 
2.2.5 Psychosis 
The association of schizophrenia with ALS has been reported (Enns et al., 1993; Howland, 
1990; Yase et al., 1972), but the pathophysiological interrelation remains unknown. There 
have been reports on a familial association (Burnstein, 1981). 
3. Measuring the disease 
The use of ALS assessment techniques such as rating scales is to monitor disease 
progression , to make outcome parameters in clinical trials comparable; and to predict 
efficacy of therapeutic strategies (Cudkowicz et al., 2004). 
Typical ALS assessment techniques comprehend (i) global scales which are based on clinical 
observation, (ii) measuring of the muscular strength, (iii) electrophysiological testing, and 
(iv) the assessment of the quality of life. 
3.1 Clinical assessment scales 
Global scales subsume (i) scores based on subjective or historic data, such as the ALS 
functional rating scale (ALSFRS) (Cedarbaum & Stambler, 1997; The ALS CNTF treatment 
study (ACTS) phase I-II Study Group, 1996), and the ALS severity scale (ALSSS) (Hillel et 
al., 1989), (ii) scores based on clinical tests such as the Norris scale (Norris et al., 1974), or the 
Appel scale (Appel et al., 1987), and (iii) scales used both for ALS and other diseases such as 
the Schwab and England global rating scale (Schwab & England, 1969), or the modified 
Ashworth spasticity scale (Bohannon & Smith, 1987). 
3.2 Muscular function testing 
Measuring of the muscular strength includes quantitative tests, maximum voluntary 
isometric contraction, handheld dynamometry, Jamar grip strength, manual muscle testing. 
Moreover, the spirometric measurement of the forced vital capacity and maximum 
voluntary ventilation can also be included in muscle tests. 
3.3 Electrophysiological measurements 
Electrophysiological testing includes compound muscle action potentials (CMAPs) and 
motor unit number estimate (MUNE) (Shefner et al., 2011) or the motor unit number index 
(MUNIX) (Nandedkar et al., 2010; Neuwirth et al., 2011).  
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A consensus conference has defined electrophysiological criteria for the diagnosis of ALS 
(de Carvalho et al., 2008). 
3.4 Assessment of the quality of life 
The quality of life is assessed by questionnaires such as the Short form – 36 (SF-36), Short 
form – 12 (SF-12), ALSQ-40, or the Sickness Impact Profile (reviewed in Epton et al., 2009; 
McGuire et al., 1997; Williams et al., 2008). 
4. The pathophysiological rationale for therapeutic interventions 
4.1 Pathophysiology of motor neuron degeneration in ALS 
Pathophysiological mechanisms involved in ALS include (reviewed in Mitsumoto et al., 
2006; Wijesekera & Leigh, 2009): 
 genetic factors (reviewed in Pasinelli & Brown, 2006; Robberecht, 2002; Ticozzi et al., 
2011),  
 excitotoxicity (reviewed in Bogaert et al., 2011; Foran & Trotti, 2009),  
 oxidative stress (reviewed in Kaur & Ling, 2008; Orrell et al., 2008),  
 mitochondrial and SOD1 dysfunction (reviewed in Benatar, 2007; Shi et al., 2010; 
Valentine et al., 2005),  
 impaired axonal transport (reviewed in Costa et al., 2010),  
 apoptosis and cell death (reviewed in Sathasivam et al., 2001),  
 neurofilament and protein aggregation such as TDP-43 proteinopathies (reviewed in 
Geser et al., 2010; Worrall et al., 2000),  
 neuro-inflammation (reviewed in Graber & Dhib-Jalbut, 2009; Holmoy, 2008; Lipton et 
al., 2007; Weydt & Moller, 2005), and  
 the lack or dysfunction of neurotrophic factors (reviewed in Maurer et al., 2008; 
Siciliano et al., 2010; Traynor et al., 2006).  
These pathophysiological mechanisms all end in motor neuron degeneration as the final 
pathway in disease progression (reviewed in Bruijn et al., 2004; Carlesi et al., 2011; Thatte & 
Dahanukar, 1997). 
To address the genetic influence in ALS, two databases have been established. The ALSoD 
database (alsod.iop.kcl.ac.uk) contains detailed information about genes involved in ALS 
pathophysiology, and the ALSGene database lists genetic association studies 
(www.alsgene.org) (Lill et al., 2011).  
4.2 Pathophysiological considerations in the planning of ALS treatment strategies 
Most pre-clinical trials in ALS research started with the pathophysiological model of the 
disease. In counteracting the pathophysiology of the disease, motor neuron survival and 
stabilization of motor neuron function is increased (reviewed in Bedlack et al., 2007; 
Carlesi et al., 2011; Fornai et al., 2011; Ilieva et al., 2009; Pradat et al., 2010; Silani et al., 
2011). 
Current strategies for treatment concepts reach for counteracting the individual 
pathophysiological actors. They including the following groups of agents: 
 Anti-excitotoxicitory drugs. Excitotoxicity is mainly modulated by the release of 
glutamate and contributes to an acute toxicity. Typical molecules involved are the 
NMDA and AMPA receptors and the glial glutamate transporter Excitatory amino-acid 
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transporters type-2 (EAAT2), which is regulating most of the extracellular glutamate 
concentration. 
 Anti-aggregation drugs. Cellular aggregates of proteins, such as the Bunina bodies, 
occur in the neuronal somata of ALS patients. The prevention of these cellular 
aggregates may also increase the survival of motor neurons. The subcellular component 
involved in the degradation of aggregates is the endoplasmic reticulum (ER). Defects in 
ER function may contribute to the formation of the protein aggregates, as well as the 
inhibition of the proteasome. 
 Suppliers of cellular energy. In ALS, mitochondrial dysfunction contributes to the 
cellular energy loss. Thus the prevention of neuronal energy depletion may increase 
and prolong neuronal survival.  
 Anti-oxidants. The generation of reactive oxygen species (ROS), such as H2O2, can 
produce major damage to the neuron. Thus specialized cellular systems exist in the cell 
to prevent oxidative damage. One of these systems include [Cu,Zn]-superoxide 
dismutase-1 (SOD1), of which mutations in humans can induce ALS. 
 SOD1 reduction techniques. The clearance of the mutated and dysfunctional SOD1 
protein may also positively influence motor neuron survival.  
 Inducers of intraaxonal transport. Molecules that signal damage in the bouton terminal 
are transported to the neuronal soma. In ALS, this transport is retricted, thus the 
damage information reaches the peri-nuclear area only delayed. 
 Drugs supporting nerve-muscle transmission. Defects in the transmission at the 
neuromuscular junction may contribute to disease progress. 
 Stabilizers of the neuro-vascular unit. The loss of proteins at the tight junctions may 
disrupt the neuro-vascular unit. Thus molecules stabilizing the tight junctions may 
ameliorate the supply of neurons with substrates. 
 Anti-inflammatory compounds. Neuroinflammation plays a role in the chronic 
detrimental processes occurring in the immediate microenvironment of the neuron. 
 Neuroprotectants. Since neurodegeneration is the general mechanism in ALS 
progression, neuroprotective drugs may prevent or slow down neuronal break-
down. 
 Anti-apoptotic compounds. Cell death is the ultimate reason in the apoptotic cascade. 
Thus compounds preventing cell death may contribute to increased survival of motor 
neurons. 
 Growth factors. Growth factors such as G-CSF, VEGF, GDNF and others can both 
stimulate the growth of novel neurons (neurogenesis) and the repair of damaged 
neurons (neuroregeneration). 
 Various techniques whereby muscles can be strengthened even in an environment 
where motor neurons are degenerating, thus maintaining motor function. 
 Gene therapy. In these approaches, the expression of endogenous proteins, such as 
growth factors, are used to increase  
 Stem cell therapies. The transplantation of various sources, such as bone-marrow 
derived stem cells (BMSC), mesenchymal stem cells (MSC), or neuronal stem cells 
(NSC), may support the microenvironment and thus the survival of motor neurons, or 
supply new motor neurons by replacing apoptotic cells.  
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5. Clinical trials in ALS 
5.1 Programmed failure in clinical trials for ALS? 
In the typical process of drug development, preclinical data such as biochemical assays, 
cellular assays, and rodent models for the disease, lead to positive results with regard to 
predefined outcome parameters, for example, the increase in muscle strength, or survival 
time. For all of the drugs listed in the next section, promising preclinical data have been 
provided and published (for review, see (Ludolph & Sperfeld, 2005)). But why did the 
majority of the clinical trials fail, when preclinical data have been so promising? 
Three major points came to my notice, when reviewing the literature: First, the animal 
models (mouse, rat, drosophila etc.) may either not sufficiently reflect the human pathology, 
or the animal pathology does not reflect human conditions (discussed in Green, 2002; 
Kiernan et al., 2011; Scott et al., 2008). Second, “ALS” is a clinical but not a 
pathophysiological entity. Thus, the inter-personal variability between patients is too big, 
and the inclusion criteria are too broad. Third, the design of the clinical trials may be 
insufficient (Aggarwal & Cudkowicz, 2008; Fornai et al., 2011; Kiernan et al., 2011; 
Maragakis, 2009), including: 
 the number of subjects is too small,  
 the time for follow-up is too short, 
 the power of the study is calculated too low, 
 the inclusion criteria are too broad,  
 the outcome measures are not well-defined and comparable, or insufficient. 
In future clinical trials, these issues should be discussed and included into the design of 
clinical ALS trials (Borasio, 1997). 
5.2 Consensus guidelines for ALS trials 
Therefore, a round table has been established to agree on minimal criteria for a “good” 
clinical trial (Miller et al., 1999). Of note, there have been substantial efforts also in other 
diseases such as stroke research to agree on clinical and pre-clinical guidelines for research, 
such as the “Stroke Therapy Academic Industry Roundtable (STAIR)” (STAIR - Stroke 
Treatment Academic Industry Roundtable, 2006).  
In the following paragraphs, I will shortly summarize the consensus guidelines for ALS trial. 
The prerequisite for any ALS trial should be a substantial diagnosis according to the criteria 
defined by the World Federation of Neurology (see above). Moreover, the inclusion criteria 
should be handled strictly, including that both sporadic and familial ALS can be entered into 
the trial. The age of the patients should be limited between 18 and 85 years of age. Symptoms 
should show a disease progression within the first six months after onset, but not more than 
five years. Additionally, also exclusion criteria have been defined, for example, the patients 
should not show sensory abnormalities, dementia, other neurological diseases, they should not 
suffer from any uncompensated medical illness, substance abuse, or psychiatric illness. Of 
note, the patients should not be taking any other investigational drug. 
The endpoints of the trial must be defined in advance, for example, survival time, muscle 
strength, or ventilator dependence are common endpoints. All trials should include a 
control group. 
The quality of life should be assessed in every efficacy trial. The statistical analysis must be 
sound and planned with sufficient power. Any co-medication must be carefully re-
considered.  
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Since there has been an early release of information about the efficacy in clinical ALS trials, 
which had to be revoked after thorough analysis, any information with regard to the 
efficacy of an investigational drug should only be released when peer-reviewed publication 
is at least imminent (with the exception of scientific meetings). The investigator is 
responsible for any conflict of interest.  
The design of ALS trials should comprehend three phases (Brooks, 1997). In phase I, toxicity 
and pharmacokinetics is tested. In phase II (pilot, exploratory, or screening trials) 
information is gathered about dose finding, preliminary efficacy, and further safety 
observations. In phase III, definitive efficacy and safety is evaluated. Phase I trials should 
incorporate a placebo control group and the follow-up should be at least six months. Phase 
II trials may use placebo controls, historic controls, or a crossover design. If the prospective 
therapeutic value aims at improvement of signs and symptoms, such as increased muscle 
strength or ameliorated function, the follow-up should be at least six months, whereas trials 
aiming at stabilization or slowing of deterioration should observe the patients’ condition for 
at least 12 months (Bedlack, 2010). All phase III trials should be placebo-controlled. The 
endpoints should include at least the survival time, assessment of strength measured by 
maximum voluntary isometric contraction, pulmonary function, and functional 
performance by the ALS rating scale. Of course, an independent data and safety monitoring 
board should be established. 
Of note, since survival times are rather short, many patients feel desperate and take 
unapproved medication out of the reach of a clinical trial. By establishing these consensus 
guidelines, this potentially dangerous drug use may be reduced (Ross, 2009). 
5.3 Overview over drug candidates in clinical ALS trials 
In the following “inventory” of clinical trials in ALS, I will give an overview over drug 
candidates used in ALS trials. I have included all interventional clinical trials registered at 
Clinicaltrials.gov (http://clinicaltrials.gov/). Information on these trials can be obtained by 
accessing the website http://ClinicalTrials.gov/show/NCTxxx, where xxx stands for the 
registration number shown below. 
Since there have been various clinical trials in the era before Clinicaltrials.gov required 
registration, and before a consensus conference established criteria for ALS trials (Miller et 
al., 1999), I have included some information on earlier trials. On the other hand, I excluded 
case reports, trials with nutritional supplements, and non-pharmacological therapeutic 
procedures such as plasma exchange, whole-body irridation, hyperbaric oxygenation, 
balneotherapy, cervico-dorsal electroshock therapy, adrenal cortex injection or stem cell 
injection, even when the stem cells are used as vehicles and vectors for the expression of 
biologicals. 
Of note, this inventory is neither comprehensive, nor does it contain all available references 
due to space restriction. It is mainly based on a selective literature search in the PubMed 
database, and summarizes recent reviews in the field (Carlesi et al., 2011; Miller et al., 2005; 
Siciliano et al., 2010; Zinman & Cudkowicz, 2011; Zoccolella et al., 2009). 
5.3.1 N-acetylcysteine 
The anti-oxidant N-acetylcysteine did not show efficacy in a phase II clinical trial (Louwerse 
et al., 1995). 
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5.3.2 AEOL-10150 
AEOL-10150 is a metalloporphyrin scavenging reactive oxygen species (ROS) (Orrell, 2006). 
It has been tested for safety and tolerability in three phase I trials, but further development 
has been halted.  
5.3.3 Amantadine (1-adamantylamine, 1-aminoadamantane) 
Amantadine shows a weak NMDA receptor antagonism and anti-cholinergic effects. In a 
cross-over study with guanidine, no benefits for ALS patients have been described (Munsat 
et al., 1981). 
5.3.4 Anakinra 
Anakinra is a recombinant antibody directed against the interleukin-1 receptor (IL-1R). IL-1 
is involved in sustaining the neuroinflammatory process. Treatment with anakinra in the 
G93A-SOD1 transgenic mouse model of ALS extended the lifespan of the animals and 
decreased neuroinflammation (Meissner et al., 2010). Thus blocking of the IL-1R may be a 
potential target in decreasing the speed of ALS progression (van der Meer & Simon, 2010). 
Currently, a phase II study (NCT01277315), designed as a riluzole add-on study, 
investigates the safety and tolerability of anakinra in ALS.  
5.3.5 Antioxidants 
In a systematic review, no evidence for a benefit of anti-oxidant treatment with regard to 
survival, neither alone, nor in combination, has been described (Orrell et al., 2008). The 
antioxidants administered in ALS patients included vitamin E, acetylcysteine, L-methionine, 
and selenium.  
5.3.6 Arimoclomol (BRX-220) 
The small molecule arimoclomol is a co-inducer of heat-shock proteins (Phukan, 2010), 
namely of HSP70 (Brown, 2007). Thus it may be used to increase endogenous cellular 
protein repair and to prevent misfolding, or aggregation, of proteins by activating molecular 
chaperones (Kalmar & Greensmith, 2009). 
Arimoclomol was tested in two phase II studies to evaluate safety and efficacy in ALS 
patients (NCT00561366) and to find a dose range and to determine  pharmacokinetic 
parameters (NCT00244244) (Cudkowicz et al., 2008; Lanka et al., 2009).  
Currently, arimoclomol is tested in a phase II/III trial in patients with SOD1-positive fALS 
(NCT00706147).  
5.3.7 Arundic acid (ONO-2506) 
Arundic acid is an enantiomeric, three carbon atom homolog of valproic acid, with anti-
inflammatory and anti-glutamatergic effects (de Paulis, 2003).  
It was tested in two phase II studies, designed as riluzole add-on, in clinical ALS trials for 
long-term safety (NCT00694941) and safety and efficacy (NCT00403104). The original 
evaluation of the trials did not show statistically significant differences between groups, but 
the subgroup analysis showed a possible positive effect for patients in early stages, namely 
within 14 months after onset of symptoms. On the other hand, patients with longer disease 
onset showed negative outcome (Thomas  Meyer, 2005).  
www.intechopen.com
  
Amyotrophic Lateral Sclerosis 
 
12
5.3.8 AVP-923 (Zenvia) 
AVP-923 is a combinational formulation containing dextromethorphan hydrobromide, 
which is an NMDA antagonist and sigma-1 receptor agonist, and quinidine sulphate, which 
inhibits the cytochrome P450 2D6 (CYP2D6) enzyme. Dextromethorphan hydrobromide 
shows a high first pass metabolism in the liver, where it is metabolized by CYP2D6. Thus 
the addition of quinidine sulphate increases the bioavailability of dextromethorphan 
hydrobromide (Olney & Rosen, 2010).  
AVP-923 was tested in two phase III trials in ALS patients with pseudobulbar affect (PBA), 
which is characterized by emotional dysregulation, such as uncontrollable outbursts of 
laughing or crying that are inappropriate to the emotions being experienced (Garnock-Jones, 
2011; Olney & Rosen, 2010). The study showed that AVP-923 ameliorates symptoms of PBA in 
ALS patients and improved quality of life and quality of relationships (Brooks et al., 2004). 
5.3.9 Azathioprine 
The immunosuppressant azathioprine in combination with prednisolone did not show a 
benefit in ALS patients (Werdelin et al., 1990). 
5.3.10 Brain-derived neurotrophic factor (BDNF) 
The neuroprotective growth factor BDNF has been evaluated in a phase I/II clinical trial 
which reported a trend for prolonged survival after subcutaneous infusion (The BDNF 
Study Group & Bradley, 1995), a result which could not be reproduced in the subsequent 
phase III clinical trial (The BDNF Study Group (Phase III), 1999). The intrathecal 
administration was safe and well-tolerated (Ochs et al., 2000). 
5.3.11 Branched-chain amino acids (BCAA) 
The branched-chain amino acids comprehend leucine, isoleucine, and valine.  
In clinical trials, branched chain amino acids did not show a beneficial effect in ALS patients 
(Tandan et al., 1996). 
5.3.12 Bromocriptine 
The dopamine agonist bromocriptine did not show a benefit in ALS patients (Szulc-
Kuberska et al., 1990).  
5.3.13 Buspirone 
The anxiolytic agent buspirone did not show a benefit in ALS patients (The ALS 
Association, 2010). 
5.3.14 Ceftriaxone 
Ceftriaxone is a ß-lactam antibiotic which also shows anti-oxidant and anti-excitotoxity 
effects (Traynor et al., 2006).  
Currently, ceftriaxone is evaluated in a phase III clinical trial in patients with ALS 
(NCT00349622).  
5.3.15 Celecoxib 
Celecoxib is an inhibitor of cyclooxygenase-2 (COX-2), an enzyme which promotes 
inflammation by releasing of inflammatory substances, such as prostaglandin E(2) (PGE2). 
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The rationale of celecoxib treatment is the reduction of PGE2 in the cerebrospinal fluid 
(CSF), thus preventing neuroinflammation and neuronal loss.  
In a phase II clinical trial (NCT00355576), celecoxib did not show a beneficial effect on the 
decline in muscle strength, motor unit number estimates, vital capacity, ALS Functional 
Rating Scale-Revised, and overall survival (Cudkowicz et al., 2006). Moreover, PGE2 levels 
in the CSF were not elevated at baseline and did not decline during treatment (Cudkowicz 
et al., 2006). In this trial, celecoxib was combined with creatinine and/or minocycline 
(Gordon et al., 2008).  
5.3.16 Ciclosporine A 
The immunosuppressant cyclosporine A did not show a benefit in ALS patients (Appel et 
al., 1988). 
5.3.17 Ciliary neurotrophic factor (CNTF) 
CNTF is a neurotrophic factor with neuroprotective properties.  
It has been tested in two clinical trials finding no effect on disease progression (ALS CNTF 
Treatment Study Group, 1996; Miller et al., 1996), but an increased trend of adverse effects 
(Miller et al., 1996).  
5.3.18 Cistanche total glycosides (CTGs) 
The glycosidic extract of the plant Cistanche spp. has a long tradition in its medicinally use in 
Traditional Chinese Medicine (TCM). It has been described as a neuroprotective agent in a 
mouse model of Parkinson’s Disease (PD) (Li et al., 2008). Currently, Cistanche Total Glycosides 
are investigated in a phase II trial (NCT00753571). Of note, the CTGs are the only agents in 
registered ALS trials without a defined chemical composition, which may impose problems in 
future comparability to other medications and effectiveness of different preparations. 
5.3.19 CK-2017357 
With regard to the loss of skeletal muscle strength, the substituted urea derivative CK-
2017357 is claimed to activate the muscle protein troponin in fast skeletal muscle fibres. A 
proposed mode-of-action is sensitizing the sarcomere to calcium, thus the neuro-muscular 
transmission is amplified, thus muscle power increases and the time to musclular fatigue is 
delayed (von Haehling et al., 2010). 
A phase IIa study (NCT01089010) was completed in 2010 and showed a trend towards 
short-term improvements in grip-strength and respiration parameters. 
5.3.20 Coenzyme Q10 
Coenzyme Q10 has been proposed to inhibit neurodegeneration. In a phase II clinical trial, it 
was well tolerated and safe (Ferrante et al., 2005), but showed no efficacy in a phase II 
futility trial (NCT00243932) (Kaufmann et al., 2009; Levy et al., 2006). 
5.3.21 Creatine 
Creatine acts as anti-oxidant and is a mitochondrial co-factor.  
It has been evaluated in several phase II clinical trials (NCT00070993, NCT00005674, 
NCT00005766) which reported no beneficial effect in ALS patients (Groeneveld et al., 2003; 
Shefner et al., 2004), as well as a phase III clinical trial (NCT00069186) (Rosenfeld et al., 2008). 
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Creatine supplementation temporarily increased maximal isometric power in ALS patients 
(Mazzini et al., 2001).  
In a phase I dose-escalation trial, creatine concentrations in the brain increased after oral 
administration (Atassi et al., 2010). 
Currently, creatine is evaluated in a phase II clinical trial (NCT01257581) in combination 
with tamoxifen in ALS patients. 
5.3.22 Cyclophosphamide 
The immunosuppressant cyclophosphamide showed only a temporary amelioration of 
symptoms in ALS patients without a long-term benefit (Gourie-Devi et al., 1997).  
5.3.23 Dexpramipexole (R-(+) pramipexole; RPPX; KNS-760704) 
Dexpramipexole is a synthetic amino-benzothiazole and the (+)-enantiomer of pramipexole 
which has dopaminergic activity and is a mitochondrial neuroprotectant by scavenging 
reactive oxygen and nitrogen species (RONS) (Cheah & Kiernan, 2010; Gribkoff & Bozik, 
2008).  
In earlier studies, RPPX reduced oxidative stress in sporadic ALS patients (Pattee et al., 
2003). RPPX has been found to be safe and tolerable (Bozik et al., 2010; Wang et al., 2008), 
but did not change ALSFRS-R (NCT00140218, NCT00600873, NCT00596115, 
NCT00647296) (Wang et al., 2008). In the open-label extension protocol, RPPX caused a 
non-significant reduction in the slope of decline in the ALSFRS-R score (NCT00931944) 
(Wang et al., 2008).  
RPPX is currently evaluated in a phase III study (NCT01281189) in ALS patients.  
5.3.24 3,4-Diaminopyridine (DAP) 
The potassium channel blocker DAP did not show a benefit in ALS patients (Aisen et al., 
1996; Aisen et al., 1995). Currently, the drug is re-evaluated after a phase I safety study 
(Bertorini et al., 2011). 
5.3.25 Dronabinol 
Dronabinol is a synthetic Δ9-tetrahydrocannabinol (Delta-9-THC, Δ9-THC, THC).  
It has been tested in a phase II study (NCT00812851) in ALS patients suffering from 
muscular cramps, where no subjective improvement of cramp intensity has been seen 
(Weber et al., 2010). 
5.3.26 Edaravone (MCI-186; NSC 2629) 
Edavarone is an anti-oxidant free radical scavenger (Takahashi, 2009). 
It has been tested in several phase II/III clinical trials (NCT00330681, NCT00415519, 
NCT00424463) for safety and efficacy. A phase II study found a possible delay in the 
progression of functional motor symptoms in ALS patients (Yoshino & Kimura, 2006). 
5.3.27 Erythropoietin (EPO) 
EPO is a hematopoietic growth factor with neuroprotective properties (Maurer et al., 2008). 
Moreover, EPO exhibited anti-inflammatory and anti-apoptotic effects. 
It has been evaluated in a phase II trial, finding no effects on survival and functional 
outcome (Lauria et al., 2009). 
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5.3.28 Escitalopram  
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) and used clinically as an 
antidepressant. 
It has been tested in a phase III clinical trial (NCT00965497) for the improvement of 
depressive symptoms and the quality of life in ALS patients.  
5.3.29 Gabapentin 
Gabapentin is an anti-convulsant with anti-glutamatergic effects, which have been proposed 
to slow down neuronal pathology (Welty et al., 1995).  
It has been tested in a phase II trial finding a smaller slope in arm strength decrase (Miller et 
al., 1996), but a subsequent phase III trial has not shown beneficial effects of (Miller et al., 
2001). No effects on neuronal integrity have been found in an MR spectroscopy study (Kalra 
et al., 2003).  
5.3.30 Gangliosides 
Gangliosides are derivatives of sialylated glycosphingolipids containing one to five sialic 
acids at various anomeric linkage sites to the core glycan. They modulate the effect of nerve 
growth factor and activate protein kinase (DeFelice & Ellenberg, 1984; Rapport, 1990).  
Gangliosides have been tested in several clinical trials without benefit for ALS patients 
(Bradley et al., 1984; Harrington et al., 1984; Lacomblez et al., 1989). 
5.3.31 Glatiramer acetate 
Glatiramer acetate is a random polymer composed of four amino acids that are found in 
myelin basic protein (MBP). It has been proposed that it inhibits neuroinflammation, 
stimulates anti-glutamatergic growth factor effects.  
In a phase II clinical trial (NCT00326625), glatiramer acetate has not shown any beneficial 
effect in ALS patients (Meininger et al., 2009). 
5.3.32 Granulocyte colony stimulating Factor (G-CSF; AX200) 
G-CSF is a hematopoietic growth and maturation factor with neuroprotective and 
neuroregenerative effects (reviewed in Maurer et al., 2008).  
G-CSF has been evaluated in a phase II study (NCT00298597) in ALS patients, finding no 
differences with regard to functional outcome between study groups, but slowing the 
progression of white matter tract destruction (Duning et al., 2011). In a second phase II trial 
(NCT00397423), the authors reported preliminary data on 13 patients with slower disease 
progression (Zhang et al., 2009). Another clinical trial did not report statistically significant 
differences between study and control group (Nefussy et al.), but a trend towards slowing 
down disease progression. 
5.3.33 Growth hormone (GH, Somatropin)  
Human growth hormone (hGH) stimulates the production and release of insulin-like 
growth factor I (IGF-1) which induces cell proliferation and differentiation (Rosenbloom, 
2009).  
GH has evaluated in a phase II trial (NCT00635960) with no effects on disease progression 
(Sacca et al., 2011). 
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5.3.34 GSK1223249 
GSK1223249 is a humanised monoclonal antibody which counteracts the inhibition of 
neurite outgrowth by Nogo-A. Currently, GSK1223249 is evaluated in a phase I study 
(NCT00875446) for safety in ALS patients. 
5.3.35 Guanidine 
In a clinical trial, guanidine caused severe side effects such as acute paralysis (Norris et al., 
1974; Norris et al., 1974). In a cross-over study with amantadine, no benefits for ALS patients 
have been described (Munsat et al., 1981). 
5.3.36 Indinavir 
The antiviral drug indinavir did not show a benefit in ALS patients (Scelsa et al., 2005). 
5.3.37 Insulin-like growth factor-1 (IGF-1) 
IGF-1 is a growth factor stimulated by the human growth hormone (hGH). It induces cell 
proliferation and differentiation (Rosenbloom, 2009).  
Whereas a first trial of IGF-1 in ALS patients reported a slower disease progression of 
functional impairment and a higher quality of life score (Lai et al., 1997), a subsequent study 
did not find beneficial effects after 9 months of treatment (Borasio et al., 1998). A phase III 
clinical trial (NCT00035815) found no beneficial effects after 2 years of treatment in ALS 
patients (Sorenson et al., 2008).  
5.3.38 Interferon  
The immunomodulators interferon-alpha (Dalakas et al., 1986; Mora et al., 1986) and 
interferon-beta (Beghi et al., 2000; Bouche et al., 1986) did not show a benefit in ALS 
patients. 
5.3.39 ISIS 333611 (ISIS-SOD1Rx) 
ISIS 333611 is an antisense oligonucleotide inhibitor of Cu/Zn superoxide dismutase (SOD1) 
(Smith et al., 2006). Currently, a phase I (NCT01041222) investigates the safety, tolerability, 
and activity familial ALS caused by SOD1 gene mutations. 
5.3.40 Isoprinosine 
The antiviral drug isoprinosine did not show a benefit in ALS patients (Fareed & Tyler, 
1971; Percy et al., 1971). 
5.3.41 Lamotrigine 
Lamotrigine is an anti-epileptic drug with anti-excitotocicity effects. It has been tested in two 
clinical trials (Eisen et al., 1993; Ryberg et al., 2003) showing no effects on disease progression.  
5.3.42 Lecithin 
The term lecithin describes a group compounds consisting of phosphoric acid, choline, fatty 
acids, glycerol, glycolipids, triglycerides, and phospholipids. Typical members comprehend  
phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol.  
In a clinical trial, lecithin did not show a benefit in ALS patients (Kelemen et al., 1982). 
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5.3.43 Leuprorelin (Leuprolide) 
Leuprorelin is a is a nonapeptide and a GnRH analog.  
It has been tested in a phase II study in combination with testosterone (NCT00004771), the 
results are awaited.  
5.3.44 Levamisole 
Levamisole is a synthetic imidazothiazole derivative with anti-helmintic and 
immunomodulatory effects. In a clinical trial, no beneficial effects have been seen for ALS 
patients (Olarte & Shafer, 1985). 
5.3.45 Lithium 
Lithium has been described as inductor of autophagy and anti-oxidant. Clinically, it is used 
as mood stabilizer. 
In a phase II study (EudraCT ), lithium did not show efficacy with regard to survival and 
keeping of patient autonomy (Chio et al.).  
In another phase II study, lithium was reported to delay disease progression (Fornai et al., 
2008), but in a follow-up, riluzole add-on phase II study (NCT00818389), lithium has been 
proven to be safe and well tolerated in ALS patients, but did not slow disease progression 
(Aggarwal et al.). Due to these findings, two other studies of lithium are currently not 
recruiting patients (NCT00925847, NCT00790582). 
5.3.46 Memantine 
Memantine non-competitive antagonist at the NMDA and AMPA glutamate receptors with 
low affinity.  
In two phase II/III clinical trials (NCT01020331, NCT00409721), memantine was safe and 
tolerated, but no efficacy has been found in ALS patients (de Carvalho et al., 2010).  
5.3.47 Methylcobalamin (E0302, mecobalamin) 
Methylcobalamin is an analog of vitamin B12, which reduces the concentration of homocystein, 
an excitatory amino acid which showed toxic effects on motor neurons by inducing apoptosis.  
ALS patients treated with high doses of methylcobalamin (MeCbl) showed an increase in 
compound muscle action potential amplitudes (CMAPs) after 4 weeks of treatment (Kaji et 
al., 1998). It increased the decline in ALS patients with regard to becoming respirator-bound 
(Izumi & Kaji, 2007). 
Methylcobalamin is currently evaluated in two phase III studies (NCT00445172, 
NCT00444613) in ALS patients  
5.3.48 Minocycline 
Minocycline has been described as anti-apoptotic and anti-inflammatory.  
In a phase III study (NCT00047723), minocycline showed harmful effects of minocycline in 
ALS patients (Gordon et al., 2007). 
5.3.49 Modafinil 
Modafinil is a psychostimulant clinically used for the treatment of narcolepsy and other 
sleep disorders.  
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It is currently evaluated in a phase IV study (NCT00614926) for the treatment of fatigue in 
ALS patients. 
5.3.50 Naloxone 
The µ opioid receptor antagonist naloxone did not show a benefit in ALS patients (Silani et 
al., 1983). 
5.3.51 Neostigmine 
The cholinesterase inhibitor did not show a benefit in ALS patients (Aquilonius et al., 
1986). 
5.3.52 Nimodipine 
The calcium channel antagonist nimodipine showed no beneficial effect in a clinical trail in 
ALS patients (Miller et al., 1996). 
5.3.53 NP001 
NP001 is a small molecule regulator of macrophage activation, which aims at restoring the 
neuroprotective state of macrophages, reducing inflammation, and normalizing the 
neuronal microenvironment. 
NP001 has been tested in a phase I trial (NCT01091142) for safety and tolerability. It is 
currently evaluated in a subsequent phase II clinical trial (NCT01281631).  
5.3.54 Olanzapine 
Olanzapine is an atypic neuroleptic drug used in psychiatry for the treatment of 
schizophrenia and other psychoses. One of its effects is also weight gain. In ALS patients, an 
involuntary weight loss of more than 10 percent of the original body weight correlates with 
an increased mortality. Thus treatment with olanzapine might increase the body weight, or, 
at least, keep it constant. 
Currently, olanzapine is evaluated in a phase II/III study (NCT00876772) in ALS 
patients. 
5.3.55 Olesoxime (TRO19622) 
Olesoxime is a neuroprotective agent with a cholesterol-like structure which is thought to 
act at the mitochondrial membrane (Bordet et al., 2010; Martin, 2010).  
Currently, olesoxime is evaluated in a phase II/III trial (NCT00868166) as add-on to riluzole 
and a phase II/III safety extension study (NCT01285583).  
5.3.56 Penicillamine 
The metal ion chelating agent penicillamine did not show a benefit in ALS patients (Conradi 
et al., 1982). 
5.3.57 Pentoxifylline 
Pentoxifylline is an anti-apoptotic drug. It has been tested in a riluzole add-on phase II 
clinical trial, which did not show efficacy, but increased mortality (Meininger et al., 
2006). 
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5.3.58 Phthalazine 
The inhibitor of cyclic adenosine monophosphate (cAMP) phosphodiesterase and cyclic 
guanine monophosphate (cGMP) phosphodiesterase phthalazinol did not show a benefit in 
ALS patients (Engel & Brooks, 1980). 
5.3.59 Physostigmine 
The acetylcholine esterase inhibitor physostigmine did not show a benefit in ALS patients 
(Norris et al., 1993). 
5.3.60 Pioglitazone  
Pioglitazone activates the nuclear receptor peroxisome proliferator-activated receptor 
gamma (PPAR-γ) (Gillies & Dunn, 2000; Kiaei, 2008). It has been used as anti-diabetic drug 
in diabetes type 2.  
In phase II clinical trial (NCT00690118), pioglitazone was found to be save and well-
tolerated, but showed no effect on ALS disease progression (Ludolph et al., 2010).  
In a riluzole add-on phase II study (NCT00919555), pioglitazone is currently evaluated in 
combination with tretinoin.  
5.3.61 Prednisolone 
The immunosuppressant prednisolone in combination with azathioprine did not show a 
benefit in ALS patients (Werdelin et al., 1990). 
5.3.62 Pyrimethamine 
The anti-malaria drug pyrimethamine was found to reduce SOD1 levels in vitro and in vivo 
in rodents as well as in humans (Lange, 2008).  
Pyrimethamine is currently evaluated in a phase I/II trial (NCT01083667) for tolerability, 
safety, and efficacy in familial ALS.  
5.3.63 Rasagiline 
Rasagiline is a monoamine oxidase type B inhibitor with neuroprotective effects.  
Rasagiline is currently evaluated in a phase II clinical trial (NCT01232738). 
5.3.64 Riluzole 
Riluzole is an anti-glutamatergic drug (Cheah et al., 2010; R.G. Miller et al., 2007).  
In two clinical trials, riluzole showed a moderate increase of about two months in survival 
after 21 and 18 months of treatment, respectively (Bensimon et al., 1994; Lacomblez et al., 
1996). An open-label phase IV study (NCT00542412) found a longer survival in riluzole-
treated patients of 92 days in median.  
In subsequent population-based trials, older patients and patients with bulbar-onset had the 
biggest beneficial effect of riluzole, but the effects were transient and lost after longer 
periods of observation (Traynor et al., 2003; Zoccolella et al., 2007).  
5.3.65 SB-509 
SB-509 is an engeineered zinc finger protein which up-regulates the transcription of the pro-
angiogenic vascular entothelial growth factor A (VEGF-A) (Liu et al., 2001), which is also 
neuroprotective and neuroregenerative (Maurer et al., 2008) 
SB-509 is currently evaluated in a phase II clinical trial (NCT00748501). 
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5.3.66 Selegiline 
The anti-depressant drug selegiline is an inhibitor of monoamino oxidase B.  
It has been tested in several clinical trials without benefit for ALS patients (Jossan et al., 
1994; Lange et al., 1998; Mazzini et al., 1994).  
5.3.67 Snake venom 
Modified snake venom as neurotoxin did not show a benefit in ALS patients (Rivera et al., 
1980). 
5.3.68 Sodium phenylbutyrate 
Sodium phenylbutyrate acts as a histone deacetylase inhibitor, therefore it improves 
transcription and stimulates post-transcriptional pathways. 
In a phase II study (NCT00107770), sodium phenylbutyrate was safe and well tolerated 
(Cudkowicz et al., 2009). 
5.3.69 Sodium valproate 
Valproic acid (VPA) is a histone deacetylase inhibitor that showed antioxidative and 
antiapoptotic properties and reduced glutamate toxicity. It is used as antiepileptic drug. 
In a phase II clinical trial (NCT00136110), VPA  has been found safe but not effective with 
regard to survival and disease progression (Piepers et al., 2009). 
5.3.70 Talampanel (GYKI 53405) 
Talampanel is a derivated benzodiazepine which is a non-competitive antagonist at the 
AMPA glutamate receptor.  
It has been evaluated in a phase II trial (NCT00982150) which showed safety and tolerability 
(Pascuzzi et al., 2010), whereas a subsequent phase II study (NCT00696332) did not show 
efficacy in ALS patients (reviewed in Carlesi et al., 2011).  
5.3.71 Tamoxifen 
The selective estrogen receptor modulator tamoxifen is an inhibitor of protein kinase C, 
which is a mediator in neuroinflammation.  
It has been evaluated in a phase II study (NCT00214110) in ALS patients (Brooks et al., 2005) 
and was recommended for a phase III trial (mentioned in Traynor et al., 2006).  
Currently, tamoxifen is evaluated in a phase II clinical trial (NCT01257581) in combination 
with creatine in ALS patients. 
5.3.72 Tauroursodeoxycholic acid (TUDCA) 
In preclinical data, tauroursodeoxycholic acid (TUDCA) has been found to be 
neuroprotective, antioxidative, and antiapoptotic in rat models of neurodegenerative 
diseases such as stroke (Rodrigues et al., 2002) and Huntington’s disease (Keene et al., 2002). 
TUDCA  is currently evaluated in a phase II study (NCT00877604) for safety and efficacy.  
5.3.73 TCH346 
TCH 346 showed neuroprotective effects by binding glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) (Mück-Seler & Pivac, 2000).  
It has been evaluated in three phase II studies (NCT00230074, NCT00072709, NCT00036413), 
where it showed no beneficial effects in ALS (R. Miller et al., 2007). 
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5.3.74 Testosterone 
The sexual hormone testosterone has been tested in a phase II study in combination with 
leuprolide (NCT00004771), the results are awaited.  
5.3.75 Tetrahydroaminoacridine (Tacrine, THA) 
The reversible inhibitor of cholinesterase THA did not show a benefit in ALS patients 
(Askmark et al., 1990). 
5.3.76 Thalidomide 
Thalidomide is a small molecule which has been used as a sedative drug in the 1950s-1960s. 
Due to its teratogenic and neuropathic adverse effects, its use was discontinued until the 
1990s, when thalidomide was introduced in oncology for its anti-angiogenic effects.  
With regard to clinical trials in ALS, thalidomide was tested in a phase II clinical trial 
(NCT00140452) (Stommel et al., 2009), with no improvement in the ALS Functional Rating 
Scale (ALSFRS) and pulmonary function testing (PFT) curves after nine months of 
thalidomide treatment. Moreover, thalidomide showed severe side effects, and did not 
affect anti-inflammatory cytokine levels.  
A second phase II clinical trial (NCT00231140) was terminated after severe adverse effects 
(Thomas Meyer, 2005).  
5.3.77 L-Threonine 
The hydroxylated essential amino acid L-threonine did not show a benefit in ALS patients 
(Blin et al., 1992; Tandan et al., 1996). 
5.3.78 Thyreotropin releasing hormone (TRH, Protirelin) 
TRH has been tested in a larger number of clinical trials, but none of them showed a benefit 
in ALS patients (Brooke et al., 1986; Brooks et al., 1987; Caroscio et al., 1986; Congia et al., 
1991; Hawley et al., 1987; Imoto et al., 1984; Klimek et al., 1989; Klimek et al., 1988; Miller & 
Warnick, 1989; Mitsumoto et al., 1986; Munsat et al., 1992; Patrignani et al., 1992; Serratrice 
et al., 1985; Stober et al., 1985; Thielen et al., 1987; Yamane et al., 1986). 
5.3.79 Tilorone 
The antiviral drug tilorone did not show a benefit in ALS patients (Olson et al., 1978). 
5.3.80 Tocopherol (Vitamin E) 
The anti-oxidant tocopherol has been evaluated in two phase II clinical trials, where 
tocopherol has been as add-on medication to riluzole in ALS patients. Both studies reported 
safe and well-tolerated drug administration, but no beneficial effect for ALS patients 
(Desnuelle et al., 2001; Graf et al., 2005). In a retrospective case-control study, high dosage of 
tocopherol decreased the risk of developing ALS (Veldink et al., 2007). 
5.3.81 Topiramate 
Topiramate is an anti-convulsant with anti-glutamatergic effects. It has been tested in a 
clinical trial without benefit for ALS patients, but with an increased rate of life-threatening 
side effects (Cudkowicz et al., 2003). 
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5.3.82 Transfer factor 
The antiviral agent transfer factor did not show a benefit in ALS patients (Jonas et al., 1979; 
Olarte et al., 1979). 
5.3.83 Tretinoin (all-trans retinoic acid) 
Tretinoin is the all-trans form of retinoic acid. It has various effects in the nervous system, 
including neuroprotection and neuroregeneration (for review, see (Lee et al., 2009)).  
In a riluzole add-on phase II study (NCT00919555), tretinoin is currently evaluated in 
combination with pioglitazone. 
5.3.84 Trypan blue and trypan red 
The antimicrobial agents trypan blue and trypan red did not show a beneficial effect in ALS 
patients (Montanari & Pessina, 1955; Schwob & Bonduelle, 1952). 
5.3.85 Vascular endothelial growth factor (VEGF, sNN0029) 
VEGF is a neuroprotectice and angiogenic growth factor (Maurer et al., 2008). It is currently 
tested in a phase I/II clinical trial (NCT00800501) for safety and tolerability. Of note, VEGF 
must be administered into the CSF.  
5.3.86 Verapamil 
The calcium channel antagonist verapamil showed no beneficial effect in a clinical trail in 
ALS patients (Miller et al., 1996). 
5.3.87 Xaliproden (SR57746) 
The 5HT1R agonist xaliproden is neurotrophic and neuroprotective. It has been evaluated in 
phase II/III trials, which showed modest effects on vital capacity, but not on survival of ALS 
patients (Lacomblez et al., 2004; Meininger et al., 2004). 
5.3.88 YAM80 
There is no drug information available for YAM80 searching literature and chemical 
databases. YAM80 is evaluated in a phase II study (NCT00886977) for safety and efficacy in 
ALS patients.  
5.3.89 Zidovudine 
The antiviral drug zidovudine did not show a benefit in ALS patients (Westarp et al., 1993). 
5.3.90 Preclinical agents 
The following agents have shown promising results in preclinical assessment, but no clinical 
trials have been conducted: 
Azathioprine, glycine, the tripeptide zVAD-fmk, AM-1241, celastrol, dantrolene, 
nordihydroguaiaretic acid, RO-28-2653, L-arginine, 5-hydroxytryptophan, N-acetylated alpha-
linked acidic dipeptidase, mechano-growth factor (MGF), hepatocyte growth factor (HGF), 
glial-derived neurotrophic factor (GDNF), promethazine and other anti-histaminergic drugs, 
calcium disodium EDTA, toluloxy propane, ammonium tetramolybdate (for details, see 
(Mitsumoto, 2009; Zoccolella et al., 2007)), and cannabis (Carter et al., 2010). 
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5.3.91 “Alternative” therapeutic approaches 
Since most clinical trials in ALS did not show a benefit for ALS patients, a number of 
“alternative” or off-label cures have been propagated. Besides severe ethical issues, these 
treatments are of experimental nature, but not in the sense of a registered trial.  
Some ALS patients who are desperately looking for a relief, tend to participate in these 
treatments, although they have to pay large amounts of money by themselves, and no 
proven, or replicable outcome has been reported in a peer-reviewed journal.  
To evaluate some of these treatments, the ALSUntangled group (www.alsuntangled.com), 
which is based on social networking of patients, clinicians, and scientists (Bedlack & 
Hardiman, 2009), reports sporadically on these treatments (see homepage for open and 
completed investigations).  
6. Outlook 
ALS remains a mysterious disease with a limited life expectancy and a deteriorating 
condition, although efforts in basic and clinical research brought some light in the 
understanding of pathophysiological aspects of MND.  
With dozens of failed neuropharmacological trials in ALS, the current concept of the 
design of clinical trials in ALS patients must be reevaluated, as well as the pre-clinical 
models.  
Future research may concentrate on the definition of ALS, maybe by the use of biomarkers, 
and on translational aspects, that is, how to transfer pre-clinical results into successful 
clinical treatment.  
7. Abbreviations 
ALS, amyotrophic lateral sclerosis 
ALSFRS, ALS functional rating scale 
ALSSS, ALS severity scale 
CNS, central nervous system 
FTD, Fronto-Temporal Dementia 
LMN, lower motor neuron 
MND, motor neuron disease 
PBP, progressive bulbar palsy 
PLS, primary lateral sclerosis 
PMA, progressive muscular atrophy 
ROS, Reactive oxygen species 
SOD1, [Zn, Cu] Superoxide dismutase type 1 
UMN, upper motor neuron 
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